Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy
Authors
- J. Lee
- V. Termglinchan
- S. Diecke
- I. Itzhaki
- C.K. Lam
- P. Garg
- E. Lau
- M. Greenhaw
- T. Seeger
- H. Wu
- J.Z Zhang
- X. Chen
- I.P. Gil
- M. Ameen
- K. Sallam
- J.W. Rhee
- J.M. Churko
- R. Chaudhary
- T. Chour
- P.J. Wang
- M.P. Snyder
- H.Y. Chang
- I. Karakikes
- J.C. Wu
Journal
- Nature
Citation
- Nature 572 (7769): 335-340
Abstract
Lamin A/C (LMNA) is one of the most frequently mutated genes associated with dilated cardiomyopathy (DCM). DCM related to mutations in LMNA is a common inherited cardiomyopathy that is associated with systolic dysfunction and cardiac arrhythmias. Here we modelled the LMNA-related DCM in vitro using patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Electrophysiological studies showed that the mutant iPSC-CMs displayed aberrant calcium homeostasis that led to arrhythmias at the single-cell level. Mechanistically, we show that the platelet-derived growth factor (PDGF) signalling pathway is activated in mutant iPSC-CMs compared to isogenic control iPSC-CMs. Conversely, pharmacological and molecular inhibition of the PDGF signalling pathway ameliorated the arrhythmic phenotypes of mutant iPSC-CMs in vitro. Taken together, our findings suggest that the activation of the PDGF pathway contributes to the pathogenesis of LMNA-related DCM and point to PDGF receptor-β (PDGFRB) as a potential therapeutic target.